Physician profile
Priya Roy
NPI 1730120494
$3,519.58
in general payments reported to CMS, 2019-2025
28 companies · $853 in 2025
The $853 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $150 · 2021: $83.59 · 2022: $117 · 2023: $308 · 2024: $1,476 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $702.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $417.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $403.78 | 2019-2025 | |
| Lilly USA, LLC | $316.41 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $306.25 | 2019-2025 | Ubrelvy |
| Abiomed | $149.70 | 2025 | |
| Abbott Laboratories | $128.50 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.88 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $99.98 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $95.45 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $89.89 | 2023-2025 | |
| Astellas Pharma US INC | $84.18 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $78.74 | 2022-2024 | Eliquis |
| Amarin Pharma, INC. | $69.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.48 | 2019-2025 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $59.08 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $56.91 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $49.11 | 2024-2025 | Opsumit, Uptravi |
| Dexcom, INC. | $38.28 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $30.14 | 2023 | |
| Merck Sharp & Dohme LLC | $28.04 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $23.56 | 2024 | Gemtesa |
| Allergan, INC. | $22.25 | 2019 | |
| Bausch Health US, LLC | $21.76 | 2019 | |
| Scilex Pharmaceuticals INC. | $21.36 | 2019 | |
| Amgen INC. | $15.92 | 2019 | |
| Shire North American Group INC | $15.66 | 2019 | |
| Aytu Biopharma, INC. | $14.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.